Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data

• Autores principales: Huijun Chen (Autor), Kensei Hashizume (Autor), Friederike Kanefendt (Autor), Christine Brase (Autor), Sebastian Schmitz (Autor), Tianxing Liu (Autor)
• Formato: Libro
• Publicado: Wiley, 2024-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract There is an unmet clinical need for effective anticoagulant therapies for the management of thromboembolic diseases that are not associated with a relevant risk of bleeding. Asundexian (BAY 2433334) is an oral, direct, small‐molecule inhibitor of activated factor XI (FXIa). Phase I data fro...